According to the company, these trials were designed to determine whether there is justification for further clinical development of lacosamide and rotigotine in these indications. The respective studies
The assets to be acquired include the intellectual property relating to the business, other intangibles, inventories and fixed assets. Zoll will, as part of this agreement, assume warranty
Under the terms of the agreement, Bial will receive E95 million consisting of an upfront payment plus milestone payments for further epilepsy approvals within Europe. Bial will maintain
New investors Auriga Partners, Cycad Group, and Alexandria Real Estate Equities also participated in the financing and were joined by returning founding investors Lux Capital Management, Polaris Venture
In Phase III studies, degarelix produced a significant reduction in levels of testosterone within three days in more than 96% of study patients. Testosterone plays a major role
Myozyme is the only approved treatment for Pompe disease, a progressively debilitating disease that manifests as a broad spectrum of clinical symptoms. The positive Committee for Medicinal Products
The FDA has indicated that it intends to advise Nuvo of its decision regarding Pennsaid approvability by August 5, 2009 under the Prescription Drug User Fee Act. Pennsaid,
The nominal 20-year patent term extends to October 13, 2024. ITMN-191 is an inhibitor of the hepatitis C virus (HCV) NS3/4A protease. ITMN-191 is being developed with InterMune’s
Sales for the quarter were $10.0 million, 11% greater than the prior year, while sales for the year were $37.6 million, 10% greater than in 2007. The company
ProLindac is Access’s novel DACH platinum prodrug currently in Phase II clinical studies which has been shown to be active in a wide variety of solid tumors in
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.